Pricing updated 2019-07-17. Prices are subject to change without notice.
MHY908 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ that increases transcriptional activity of PPARα and PPARγ in a luciferase reporter assay in AC2F rat liver cells when used at a concentration of 5 µM.1 In vivo, MHY908 (3 mg/kg per day) reduces serum glucose, triglyceride, and insulin levels and improves hepatic steatosis by reducing hepatic triglyceride levels and lipid droplet accumulation in db/db mice and 20-month-old rats.1,2 It reduces peroxynitrite and COX-2 levels, reactive oxygen species (ROS) production, and Akt phosphorylation in isolated kidney from 20-month-old rats when administered at a dose of 3 mg/kg.2 MHY908 inhibits mushroom tyrosinase (IC50 = 8.19 µM).3 It also inhibits increases in melanin content in α-melanocyte stimulating hormone-induced B16/F10 murine melanoma cells when used at a concentration of 10 µM.
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Park, M.H., Park, J.Y., Lee, H.J., et al. Potent anti-
2. Park, M.H., Kim, D.H., Kim, M.J., et al. Effects of MHY908, a new synthetic PPARα/γ dual agonist, on inflammatory responses and insulin resistance in aged rats J. Gerontol. A Biol. Sci. Med. Sci. 71(3), 300-309 (2016).
Park, M.H., Kim, S.J., Jeong, H.O., et al. Inhibition of melanogenesis by 2-